It included three patients with breast cancer, of whom one showed stable disease with an approximately 20% increase in tumor size, one showed a reduction in tumor size but elevated MDM2 levels, and one showed a progressive tumor increase of >20%. This evidence concerns the gene MDM2 and neoplasm.